ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock OBSV vs. KZR, FGEN, MRNS, INKT, ALLK, SCLX, CALC, GRCE, SRZN, and OKURShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Kezar Life Sciences (KZR), FibroGen (FGEN), Marinus Pharmaceuticals (MRNS), MiNK Therapeutics (INKT), Allakos (ALLK), Scilex (SCLX), CalciMedica (CALC), Grace Therapeutics (GRCE), Surrozen (SRZN), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical products" industry. ObsEva vs. Kezar Life Sciences FibroGen Marinus Pharmaceuticals MiNK Therapeutics Allakos Scilex CalciMedica Grace Therapeutics Surrozen OnKure Therapeutics ObsEva (NASDAQ:OBSV) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability. Does the MarketBeat Community prefer OBSV or KZR? ObsEva received 182 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. However, 57.08% of users gave Kezar Life Sciences an outperform vote while only 49.53% of users gave ObsEva an outperform vote. CompanyUnderperformOutperformObsEvaOutperform Votes31949.53% Underperform Votes32550.47% Kezar Life SciencesOutperform Votes13757.08% Underperform Votes10342.92% Do institutionals & insiders believe in OBSV or KZR? 17.5% of ObsEva shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, OBSV or KZR? ObsEva has higher revenue and earnings than Kezar Life Sciences. Kezar Life Sciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEva$20.11M0.00-$58.38M-$0.92N/AKezar Life Sciences$7M4.18-$101.87M-$10.82-0.37 Is OBSV or KZR more profitable? Kezar Life Sciences' return on equity of -54.95% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% Kezar Life Sciences N/A -54.95%-46.11% Which has more volatility and risk, OBSV or KZR? ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Do analysts rate OBSV or KZR? Kezar Life Sciences has a consensus target price of $39.50, suggesting a potential upside of 886.02%. Given Kezar Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than ObsEva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer OBSV or KZR? In the previous week, Kezar Life Sciences had 3 more articles in the media than ObsEva. MarketBeat recorded 4 mentions for Kezar Life Sciences and 1 mentions for ObsEva. Kezar Life Sciences' average media sentiment score of 0.91 beat ObsEva's score of 0.00 indicating that Kezar Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ObsEva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kezar Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKezar Life Sciences beats ObsEva on 9 of the 16 factors compared between the two stocks. Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$6.51B$5.35B$8.44BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.119.1526.9119.77Price / SalesN/A259.30390.06119.10Price / CashN/A65.8538.2534.62Price / BookN/A6.476.794.52Net Income-$58.38M$144.21M$3.23B$248.23M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150KZRKezar Life Sciences4.1523 of 5 stars$4.23+0.2%$39.50+833.8%-48.3%$30.90M$7M-0.3260Gap UpFGENFibroGen4.377 of 5 stars$0.31-0.8%$10.00+3,174.4%-72.1%$30.86M$29.62M-0.25570MRNSMarinus Pharmaceuticals1.8807 of 5 stars$0.55-0.2%$4.79+771.6%-58.7%$30.32M$30.99M-0.22110News CoverageAnalyst ForecastINKTMiNK Therapeutics2.6036 of 5 stars$7.60+8.1%$37.50+393.4%-22.2%$30.14MN/A-1.9530Earnings ReportAnalyst RevisionALLKAllakos4.2132 of 5 stars$0.33+0.3%$2.00+506.8%N/A$29.79MN/A-0.16190SCLXScilex1.5552 of 5 stars$4.10+2.2%$455.00+10,997.6%-87.8%$28.50M$56.59M-4.9480High Trading VolumeCALCCalciMedica2.4232 of 5 stars$2.01+0.5%$18.00+795.5%-67.6%$28.08MN/A-1.8630GRCEGrace Therapeutics1.8472 of 5 stars$2.72flat$12.00+341.2%N/A$27.58MN/A-2.34N/AGap UpSRZNSurrozen2.9921 of 5 stars$8.00-4.2%$38.50+381.3%-24.7%$26.25M$10.66M-0.3280OKUROnKure Therapeutics2.9271 of 5 stars$1.95+1.6%$32.33+1,558.1%N/A$26.20MN/A-0.16N/AInsider TradeGap Up Related Companies and Tools Related Companies Kezar Life Sciences Alternatives FibroGen Alternatives Marinus Pharmaceuticals Alternatives MiNK Therapeutics Alternatives Allakos Alternatives Scilex Alternatives CalciMedica Alternatives Grace Therapeutics Alternatives Surrozen Alternatives OnKure Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBSV) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
